Saturday, Sep 26, 2020 | Last Update : 09:38 PM IST

186th Day Of Lockdown

Maharashtra130045899280634761 Andhra Pradesh6614585881695606 Tamil Nadu5693705138369148 Karnataka5572124503028417 Uttar Pradesh3785333136865450 Delhi2644502284365147 West Bengal2410592110204665 Odisha201059165432820 Telangana1838661524411091 Bihar175898161510881 Assam167374136712625 Kerala160935111327636 Gujarat1303911105923394 Rajasthan1247301042881412 Haryana1205781012731273 Madhya Pradesh117588932382152 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880
  Life   Health  14 Dec 2019  Can fish oil based drug prevent heart disease?

Can fish oil based drug prevent heart disease?

AP
Published : Dec 14, 2019, 2:00 pm IST
Updated : Dec 14, 2019, 2:00 pm IST

US approves fish oil-based drug for cutting heart risks.

High triglycerides can clog arteries and boost chances of developing heart disease, suffering heart attacks or strokes. (Photo: AP)
 High triglycerides can clog arteries and boost chances of developing heart disease, suffering heart attacks or strokes. (Photo: AP)

Trenton: US regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills.

Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood. The Food and Drug Administration allowed its use in a far bigger group of adults with high, but less extreme, triglyceride levels who have multiple risk factors such as heart disease and diabetes.

 

In patient testing, it reduced risks of potentially deadly complications including heart attacks and strokes about 25 per cent.

Amarin, the drug’s maker, set a list price of USD303.65 per month. What patients pay will vary by insurance, and Amarin said it will offer financial help.

The Irish drugmaker estimates the new approval makes Vascepa, which is pronounced vas-EE’-puh and also is called icosapent ethyl, appropriate for up to 15 million US patients.

High triglycerides can clog arteries and boost chances of developing heart disease, suffering heart attacks or strokes, needing a bypass or artery-clearing procedure, or being hospitalized for chest pain — just like high cholesterol and elevated blood pressure can do.

 

Amarin funded a five-year study of nearly 8,200 patients at high cardiac risk who were already taking medicines to lower bad cholesterol or control diabetes. The half who took Vascepa capsules along with those medicines had a 25 per cent lower chance of heart complications and a 20 per cent lower risk of death, compared with those adding dummy capsules of mineral oil to their medicines.

Slightly more patients getting Amarin’s drug had an irregular heartbeat than those taking the dummy capsules, but other side effects were minor.

Previous studies testing other fish oil drugs to cut cardiac risk had flopped.

Heart disease affects an estimated 121 million American adults, causes about one in three deaths and costs more than USD500 billion annually for treatment, according to the American Heart Association. Millions of Americans take nonprescription supplements of fish oil, also called omega-3 fatty acids, for their supposed heart benefits, but their dosages are far below Vascepa’s potency.

 

Vascepa sales brought Amarin just USD287 million over 2019′s first nine months, but analysts forecast the much-broader approval could boost annual sales to USD3 billion or more.

Tags: heart disease, fish oil, cardiovascular health